ORX 101
Alternative Names: ORX-101Latest Information Update: 28 Sep 2022
Price :
$50 *
At a glance
- Originator B & G Partners
- Class Antineoplastics; Phenothiazines; Small molecules
- Mechanism of Action Integrin alpha3beta1 inhibitors; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diffuse intrinsic pontine glioma
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Diffuse intrinsic pontine glioma in USA
- 02 Dec 2015 OncoRx Pharmaceuticals has patent protection for its drugs for the treatment of therapy-resistant malignant tumours in USA
- 23 Sep 2015 Preclinical trials in Diffuse intrinsic pontine glioma in USA (unspecified route)